United Therapeutics (NASDAQ:UTHR) is a biotechnology company that focuses on developing and commercializing products to address the unmet medical needs of patients with chronic and life-threatening conditions. The company is well-known for its treatments for pulmonary arterial hypertension (PAH) and pediatric neuroblastoma. Key competitors in the PAH market include Actelion Pharmaceuticals and Gilead Sciences.
On October 29, 2025, Terrance Flynn from Morgan Stanley set a price target of $447 for UTHR. At that time, the stock was trading at $449.70, slightly above the target by about 0.60%. This suggests that the market had a positive outlook on the stock, possibly due to recent performance and future growth potential.
United Therapeutics reported a 12% increase in earnings per share for the third quarter of 2025, reaching $7.16. This exceeded the Zacks Consensus Estimate of $6.89, driven by strong sales of key products like Tyvaso and Orenitram. Despite this, the company's revenues were $799.5 million, falling short of the expected $818 million, but still showing a 7% year-over-year growth.
Tyvaso sales were particularly strong, with a 10% growth, and Tyvaso DPI saw a 22% increase. The TETON-2 study showed that Tyvaso improved lung function in patients with idiopathic pulmonary fibrosis (IPF), indicating potential for future growth. This positive development could contribute to the stock's recent performance and market confidence.
Currently, UTHR is trading at $455.32, reflecting a significant increase of 9.63% or $39.98. The stock has fluctuated between $415.26 and $479.50 today, with the latter being its highest price over the past year. The lowest price for the year was $266.98. UTHR has a market capitalization of approximately $20.59 billion, with a trading volume of 1,829,106 shares.
